13G Filing: James E. Flynn and Aclaris Therapeutics Inc (ACRS)

Page 9 of 14

Page 9 of 14 – SEC Filing

CUSIP No. 00461U105 13G Page 9
of 11 Pages
(j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance
with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned**:

Deerfield Mgmt, L.P. – 1,769,377 shares

Deerfield Management Company,
L.P. – 1,769,377 shares

Deerfield Partners, L.P. –
1,107,639 shares

Deerfield International Master
Fund, L.P. – 604,322 shares

Deerfield
Special Situations Fund, L.P.
57,416 shares

James E. Flynn – 1,769,377 shares

(b) Percent of class**:

Deerfield Mgmt, L.P. – 5.90%

Deerfield Management Company,
L.P. – 5.90%

Deerfield Partners, L.P. –
3.69%

Deerfield International Master
Fund, L.P. – 2.01%

Deerfield
Special Situations Fund, L.P.
.19%

James E. Flynn – 5.90%

(c) Number of shares as to which such person has**:
(i) Sole power to vote or to direct the vote: All Reporting Persons 0
(ii) Shared power to vote or to direct the vote:

Deerfield Mgmt, L.P. – 1,769,377

Deerfield Management Company, L.P. – 1,769,377

Deerfield Partners, L.P. – 1,107,639

Deerfield International Master Fund, L.P. – 604,322

Deerfield Special Situations Fund, L.P.
57,416

James E. Flynn – 1,769,377 

(iii)

Sole power to dispose or to direct the disposition of:

All Reporting Persons – 0
(iv)

Shared power to dispose or to direct the disposition
of:

Deerfield Mgmt, L.P. – 1,769,377

Deerfield Management Company, L.P. – 1,769,377

Deerfield Partners, L.P. – 1,107,639

Deerfield International Master Fund, L.P. – 604,322

Deerfield Special Situations Fund, L.P.
57,416

James E. Flynn – 1,769,377

**See footnotes on cover pages which are incorporated by reference
herein.

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 9 of 14